On November 10, 2022 CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, reported new preclinical data highlighting the potential of the company’s tumor-reactive NK (TRACK-NK) cell program, CYTO-102, to potently and selectively kill tumor cells with the mechanism of action of antibody-dependent cellular cytotoxicity (Press release, CytoImmune Therapeutics, NOV 10, 2022, View Source [SID1234623776]). The data are being presented today during a poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, being held November 10-13, 2022, virtually and in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CytoImmune has engineered its TRACK-NK (CYTO-102) cells for clinical use by inducing expression of soluble IL-15 that is designed to activate and expand the endogenous immune response in patients. Further, these cells are designed to act as "serial killer" cells, making them capable of attacking multiple tumor cell targets in a short period of time. CytoImmune is currently advancing CYTO-102 in a Phase 1 clinical trial in patients with non-small cell lung cancer (NSCLC).

"Serial killer NK cells are rare in the immune system but have immense potential to deliver rapid anti-tumor responses through direct cell killing for the treatment of a number of challenging cancers," said Michael Caligiuri, M.D., co-founder and chief scientific officer of CytoImmune. "Combined with the ability of these cells to stimulate the patient’s own immune system to fight cancer cells, we’ve designed our TRACK-NK cells to deliver the most potent anti-tumor response possible, while maintaining good tolerability. We look forward to sharing these exciting data with the scientific community at SITC (Free SITC Whitepaper) and the opportunity to bring meaningful treatments forward for patients with cancer."

The findings to be presented highlight the dual mechanism of these cells to both induce tumor-reactivity by activating and expanding immune response as well as serial killing of multiple target cells. To evaluate their potential, CytoImmune conducted several in vitro and in vivo studies with TRACK-NK (CYTO-102). Findings showed:

TRACK-NK (CYTO-102) cells led to serial killing of both hematologic tumor cells (lymphoma) and solid tumor cells (NSCLC) in vitro
Further, when combined with tumor antigen directed monoclonal antibodies, TRACK-NK (CYTO-102) cells led to enhanced serial killing and conversion of an NK-insensitive cell line to sensitive in vitro
TRACK-NK (CYTO-102) cells effectively "cycle" the expression of CD16 and as is common for serial killers, expression is rapidly restored following resting or cryopreservation of the cells
"We are very excited to present these new preclinical data with our TRACK-NK cells, demonstrating the potential dual tumor-reactive and serial killing mechanism, aimed at providing potent and durable anti-tumor responses," said Christina Coughlin, M.D., chief executive officer of CytoImmune. "With CYTO-102, we have the potential to offer an off-the-shelf therapy for patients with cancer and these data support its continued evaluation. Our Phase 1 trial with CYTO-102 is ongoing, and we look forward to building a further understanding of its full potential in humans with initial clinical data expected in 2023."

On November 10, 2022 Repertoire Immune Medicines reported that conducted with the company’s proprietary DECODE platform, which characterizes the cellular response to disease, identifying novel therapeutic targets in human papillomavirus (HPV) 16 and HPV 33-positive tumors (Press release, Repertoire, NOV 10, 2022, View Source [SID1234623775]). This research is part of Repertoire’s collaboration with Dana-Farber Cancer Institute to advance discovery and development of treatments for HPV-positive oropharyngeal (head and neck) cancers and was presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (SITC 2022) 37th Annual Meeting, in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"One of the growing challenges in HPV-positive cancer treatment is that we are observing an increase in the prevalence of HPV high-risk genotypes associated with worse outcomes," said Glenn J. Hanna, M.D., director of the Center for Salivary and Rare Head and Neck Cancers at Dana-Farber Cancer Institute.1 "The research we conducted with the DECODE platform suggests that current treatments may not be targeting some key antigens active in these genotypes, which has significant implications for patient treatment. Importantly, we now have data that point to antigens active in driving these malignancies, which we can use to develop novel targeted medicines."

The DECODE platform is a suite of integrated experimental and computational technologies designed to decipher the immune synapse, the complex interface between T cells and the epitopes they recognize. DECODE is being used to assess the immunogenicity profile of HPV 16 and HPV 33-positive tumors in oropharyngeal squamous cell carcinoma (OPSCC). By characterizing the cellular response to these cancers, it is possible to identify the specific epitopes eliciting the strongest T cell activity in tumors and the associated T cell receptors (TCRs) binding those epitopes, identifying what may be ideal targets for immunotherapies.

"Using the DECODE platform, we have a window into the mechanisms involved in the immune surveillance of cancer, which offers us the ability to develop highly selective immune-based medicines," said Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines. "The data we presented today from our DECODE platform illustrate the immunogenic profile of HPV 16 and HPV 33-positive tumors, providing us with insights into the specific epitopes that are drivers of these cancers and are targets for new immunotherapies."

HPV infection is a risk factor for several cancers, including OPSCC. Many therapeutic approaches for OPSCC target the epitopes from E6 and E7 antigens of HPV; however, these treatments are not successful for every patient and new approaches based on highly prevalent immunodominant epitopes in both early-stage and relapsed/refractory patients may offer more effective treatment for certain genotypes of HPV-positive OPSCC.

DECODE Discovery in HPV 16 and HPV 33-Positive Oropharyngeal Squamous Cell Carcinoma

In order to better characterize the cellular response to HPV-positive OPSCC across common human leukocyte antigen (HLA) haplotypes, biopsies were collected from patients with HPV 16-positive or HPV 33-positive OPSCC. All samples were assessed using the DECODE platform.

In patients with HPV 16-positive tumors, effective cytotoxic responses were induced by antigens E1 and E2 of HPV, which were substantially greater than the response driven by E5, E6 and E7. These findings suggest HPV 16 E1 and E2-directed immunotherapy may be effective among patients with HPV 16-positive OPSCC expressing these antigens.

HPV 33-positive OPSCC is characterized with an inferior survival rate compared to HPV 16-positive head and neck cancers. To better understand the potential reasons for this difference in outcomes, a comparison of the immunogenic profile of HPV 16 and HPV 33-positive tumors was conducted with DECODE.

HPV 33-positive tumors in this research had fewer cytotoxic CD8+ T cells and fewer activated antibody-secreting B cells compared to HPV 16-positive tumors. In addition, the HPV 33-positive tumors had poor antigen presentation and deficient HPV E7 recognition by T cells. Both genotypes of OPSCC are typically treated with the same standard of care, but the differences observed in the HPV 33-positive tumor composition and cellular phenotype would be expected to lead to a poor immune response and may be the cause of the inferior treatment outcomes observed in the population of patients with this tumor genotype.

Additional detail from this ongoing research is included in Poster #86, HPV16 E1 and E2 elicit a robust cytotoxic immune response in virally driven Oropharyngeal Squamous Cell Carcinoma, and in Poster #1404, HPV33-driven Oropharyngeal Squamous Cell Carcinomas are increasing in prevalence and are characterized by low CD8 infiltration and epitope presentation deficiencies.

These data, as well as the company’s early research in targeting interleukin-2 (IL-2) to solid tumors, will be presented during the poster session at the SITC (Free SITC Whitepaper) congress on Thursday, November 10, through Friday, November 11, 2022, 9:00 a.m. – 9:00 p.m. EST.

About the DECODE Platform

The DECODE platform is a powerful discovery engine that characterizes essential elements of the immune synapse. In particular, the platform identifies T cell receptor-antigen pairs in the context of other important features of the immune synapse, such as T cell function and how antigens are presented by molecules on antigen-presenting cells, known as major human leukocyte antigen, or HLA, molecules. Repertoire intends to utilize these insights into key drivers that govern immune function to design and develop novel immune product candidates.

On November 10, 2022 OncoNano Medicine, Inc. reported the presentation of data on its pre-clinical candidate ONM-501 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) in Boston, Massachusetts (Press release, OncoNano Medicine, NOV 10, 2022, View Source [SID1234623774]). ONM-501, OncoNano’s lead therapeutic program in development, is a dual-activating STING (Stimulator of Interferon Genes) agonist advancing towards a first in human trial planned to be initiated in the first half of 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Previously published data has demonstrated the differentiated mechanism of ONM-501 with dual "burst" and "sustained" STING activation, enhanced cytosolic delivery and tumor retention through encapsulation of an endogenous STING agonist – cGAMP with OnocoNano’s proprietary STING-activating OMNI polymeric micelles. These two mechanisms operate in concert to activate STING and potentiate this activation, providing potent anti-tumor efficacy as a monotherapy and in combination with anti-PD1 in multiple preclinical mouse models with both "hot" and "cold" tumor microenvironments. In vivo PD analysis confirmed STING activation, enhanced tumor lymphocyte infiltration, and tumor PD-L1 upregulation by ONM-501, and demonstrated the target-engagement activity of ONM-501 in multiple species, and high tolerability in rodents and non-human primates, making it a promising therapeutic candidate for clinical evaluation.

"The results presented here confirm many of our hypotheses regarding the potential of ONM-501 to provide a robust therapeutic index of immune activating STING activity that may be differentiated from other STING agonists. This is why we are so buoyed by the continued positive preclinical results for ONM-501, underscoring its potential as a monotherapy and in combination with anti-PD1 in multiple ‘hot’ and ‘cold’ murine syngeneic tumor models," said Kartik Krishnan, MD, PhD, Chief Medical Officer at OncoNano. "We look forward to bringing ONM-501 to the clinic in 2023 as we continue on our mission to deliver critical new treatments to patients in need."

On November 10, 2022 AbCellera (Nasdaq: ABCL) reported the release of new data on its T-cell engager (TCE) platform at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022 (Press release, AbCellera, NOV 10, 2022, View Source [SID1234623773]). AbCellera’s poster presentation describes the expansion, further characterization, and validation of a diverse panel of CD3-binding antibodies that can be used to develop T-cell engagers for cancer treatments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The robust data package we are presenting at SITC (Free SITC Whitepaper) demonstrates that our panel includes antibodies that are distinct from molecules commonly used for CD3 T-cell engager development," said Bo Barnhart, Ph.D., VP, Translational Research at AbCellera. "By combining this panel with the OrthoMab bispecifics platform and high-throughput antibody analytics, we have shown that we can rapidly identify developable T-cell engagers that balance potent cytotoxicity and low cytokine release."

CD3 T-cell engagers are bispecific antibodies that redirect T cells to kill tumor cells. Developing effective T-cell engagers requires two parental antibodies: a CD3-binding arm that fine-tunes T-cell activation and a tumor-binding arm with high specificity for cancer cells. Pairs of parental antibodies that work well together are rare, creating a need for diverse panels of developable antibodies that can be combined and tested at scale to find optimal clinical candidates.

To address the paucity of anti-CD3 antibodies for TCEs, AbCellera used its integrated antibody discovery, characterization, and engineering technologies to discover and validate an extensive panel of fully human CD3-binding antibodies. New data presented at SITC (Free SITC Whitepaper) includes epitope binning analysis, revealing antibodies with species cross-reactivity that bind epitopes distinct from commonly used parental antibodies, such as SP34-2. AbCellera also conducted a second discovery campaign strategically designed to enhance the number of cross-reactive antibodies in the panel, resulting in hundreds of additional unique antibody sequences to be characterized.

Developing bispecific antibodies that potently eliminate cancer cells without inducing toxicity has been a significant challenge limiting T-cell engager development. In a proof-of-concept study, AbCellera used its OrthoMabTM bispecifics platform to create CD3 x EGFR T-cell engagers. High-throughput functional and biophysical assays identified potent tumor-cell killing T-cell engager molecules that maintained low levels of cytokine production without the need for further engineering or optimization.

"We debuted our T-cell engager platform at the AACR (Free AACR Whitepaper) annual meeting in April of this year, and in less than six months, we have greatly expanded the data package supporting this platform," said Murray McCutcheon, Ph.D., Senior VP, Corporate Development at AbCellera. "The remarkable progress demonstrates the speed of AbCellera’s antibody discovery engine, the quality of the antibodies in our T-cell engager panel, and the potential impact it has for partners looking to accelerate development of new cancer treatments."

On November 10, 2022 Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, reported that new, preclinical data highlighting the potential of the company’s lead program, ANK-101, an IL-12-based treatment, to deliver potent anti-tumor responses following intratumoral administration will be presented during a poster presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting. SITC (Free SITC Whitepaper) is being held November 10-13, 2022, virtually and in Boston (Press release, Ankyra Therapeutics, NOV 10, 2022, View Source [SID1234623772]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IL-12 is a potent cytokine that can promote innate and adaptive anti-cancer immunity, but its clinical development has been limited by toxicity when delivered systemically. Intratumoral administration can expand the therapeutic window of IL-12; however, it is limited by rapid drug clearance from the tumor, thereby reducing efficacy, necessitating frequent administration, and increasing systemic accumulation. To overcome the limitations of traditional cytokine therapeutics, Ankyra has leveraged its Anchored Immunotherapy Platform to develop ANK-101, a stable complex of a modified IL-12 cytokine with aluminum hydroxide (Alhydrogel). Alhydrogel, an FDA-approved adjuvant for use in human and veterinary vaccines, acts as a scaffold to locally retain the potent activity of IL-12 following intratumoral administration in order to improve its therapeutic window.

"We are excited to present these findings from our ANK-101 program at this year’s SITC (Free SITC Whitepaper) Annual Meeting, which highlight the potential of our Anchored Immunotherapy Platform to enable an expanded therapeutic window for cytokines like IL-12," said Howard Kaufman, M.D., president and chief executive officer. "IL-12 is well known to have the ability to offer a meaningful treatment option for patients with cancer, but that has historically been limited by toxicity and dosing challenges. By leveraging our platform based on Alhydrogel anchoring, we believe we can overcome the shortcomings of systemic IL-12 to deliver a safe and effective treatment option. This is supported by our extensive preclinical work with ANK-101, where we’ve observed potent anti-tumor responses with good tolerability, and we look forward to its continued advancement towards clinical studies."

The data to be presented today are from several preclinical studies in mouse models and non-human primates (NHPs). Findings include:

Administration of mANK-101 (murine surrogate) led to enhanced tumor retention and reduced systemic exposure compared to un-anchored IL-12
Administration of mANK-101 was efficacious in diverse syngeneic tumor models, including large tumors, leading to substantial reductions in tumor volume after one or two injections
mANK-101 treatment induced a profound remodeling of the tumor microenvironment with increased T- and NK-cell infiltration and activation, shifts to pro-inflammatory myeloid cell phenotypes, and increased markers of antigen presentation and co-stimulation as measured by Nanostring, IHC, and scRNA-seq
ANK-101 administration in NHPs was well tolerated across all dose levels evaluated
Ankyra is currently advancing ANK-101 through Investigational New Drug (IND) enabling studies and plans to submit an IND to the U.S. Food and Drug Administration in the second quarter of 2023.